Nanjing Vazyme Biotech Co Ltd
SSE:688105
Nanjing Vazyme Biotech Co Ltd
Total Liabilities & Equity
Nanjing Vazyme Biotech Co Ltd
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nanjing Vazyme Biotech Co Ltd
SSE:688105
|
Total Liabilities & Equity
¥5.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
87%
|
CAGR 10-Years
N/A
|
Beigene Ltd
HKEX:6160
|
Total Liabilities & Equity
¥41.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Liabilities & Equity
¥20.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities & Equity
¥15.7B
|
CAGR 3-Years
65%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities & Equity
¥50.2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
43%
|
CAGR 10-Years
34%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Liabilities & Equity
¥6.3B
|
CAGR 3-Years
103%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing Vazyme Biotech Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
5.7B
CNY
Based on the financial report for Dec 31, 2023, Nanjing Vazyme Biotech Co Ltd's Total Liabilities & Equity amounts to 5.7B CNY.
What is Nanjing Vazyme Biotech Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
87%
Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Nanjing Vazyme Biotech Co Ltd have been 53% over the past three years , 87% over the past five years .